男童特发性矮小接受和不接受生长激素治疗最终身高的比较

Comparison of final adult height in boys with idiopathic short stature accepted growth hormone treatment or not

目的了解基因重组生长激素（r—hGH）是否可以改善特发性身材矮小（ISS）男童的最终成人身高（FAH）。方法测量了16例当年诊断为ISS男童FAH，共分两组，其中观察组9例未予r-hGH治疗，治疗组7例接受了r-hGH治疗，剂量为0．1～0．13U·kg^-1·d^-1，临睡前皮下注射，疗程为6—20（11．9±5．2）个月。结果治疗组平均FAH较观察组的平均FAH有明显提高（t=2．219，P〈0．05）。结论r-hGH可改善ISS男童的FAH，但要早期治疗，疗程越长效果越明显。

Objective In order to understand whether recombinant human growth hormone（r-hGH） can improve the idiopathic short stature（ISS） boys＇ final adult height（FAH）. Methods We measured 16 eases diagnosed as ISS boys FAH ,divided into 2 groups ,of which 9 cases were not given r-hGH treatment, treatment group,7 patients received r-hGH treatment,a dose of 0.1-0.13U·kg^-1·d^-1 ,before going to sleep subcutaneous injection,duration of treatment was 6 - 20 months （ 11.9±＋ 5.2 months）. Results The treatment group compared with the average FAIl FAH observation group had significantly improved the average（t = 2. 219,P 〈 0. 05）. Conclusion r-hGH can improve the ISS boys FAH, but early treatment, the longer the course the more obvious effects.